Current Clinical and Medical Education

Received 19 Jun 2024 | Revised 22 Jun 2024 | Accepted 6 Jul 2024 | Published Online 4 Aug 2024

Published By: Vision Publisher

CCME 02 (8), 140-151

ISSN 2942-0792

Radiotherapy for Spinal Tumors: Benign and Malignant Primary Tumors, Efficacy of SABR for the Treatment of Spinal Tumors

Amal Khudair Abbas Al-Tai[1], Zahraa Falih Kareem Alrubaey[2], Iyad Faza Turki Al Kanaan[3]

[1,2]Al-Hilla University College, Medical physics, Iraq

[3]Al-Kitab University College, Department of Technology Engineering, Medical Devices, Iraq

ABSTRACT:

For patients with primary spine tumours, stereotactic body radiation (SBRT) is becoming the treatment of choice. Patients with primary spine tumours that cannot be surgically removed can undergo SBRT-based regimens as a neoadjuvant treatment or as an adjuvant treatment before final surgery. A number of primary spinal tumours are finding that SBRT-based therapies improve structural, mechanical, and functional results, making them the radiation treatment of choice. Due to its ability to safely increase dosages and overcome the radioresistant phenotype shown in certain primary spine tumours, SBRT and specifically single fraction radiosurgery is an encouraging new approach to treating these tumours. Curative treatment with minimal neurologic, mechanical, and functional damage is possible with SBRT alone or in conjunction with open surgery. Longer follow-up and the creation of prospective clinical studies will determine the long-term efficacy of spinal radiosurgery.

Keywords: Spinal Tumors: Benign and Malignant Primary, Radiotherapy, SABR, Treatment.

Corresponding Author: Amal Khudair Abbas Al-Tai†, Al-Hilla University College, Medical physics, Iraq

Introduction

When local failure is catastrophic and tumours abut sensitive vital normal tissues such the spinal cord, cauda equina, and oesophagus, stereotactic body radiation (SBRT) is being used more and more to manage primary benign and malignant spine tumours. The sacrum, spinal cord, and movable spine all perform essential mechanical, functional, and neurological roles, making primary spinal tumours difficult to cure. To achieve cure, local control is essential. However, en bloc resection strategies are rarely an option for primary spine tumours due to the tumor's involvement in multiple compartments and close relationships with important normal structures. Wide resection often results in significant loss of neurologic and mechanical function. Following these en bloc surgical procedures, patients will need to undergo extensive rehabilitation and employ sophisticated tissue reconstruction techniques. Additionally, recurrence is common following intralesional resection methods, even after adjuvant radiation therapy has been administered. Research has demonstrated that SBRT-based treatments, whether with or without reduced surgical resection, achieve similar levels of local control as aggressive en bloc resection techniques, but without the functional and medical concerns [1-3]. Conventionally fractionated radiation therapy treatment plans for primary spine tumours are not always up to par because the doses that are prescribed are constrained by the tolerance of nearby important normal structures, which prevents the administration of doses that are associated with strong local control. Since SBRT uses image guidance to correct inter- and intrafraction motion and sophisticated inverse treatment planning algorithms to provide extremely conformal dose distributions, it is an attractive option for treating spine tumours. The ability to maximise the therapeutic radio of treatment is achieved, unlike with non-SBRT treatments [4, 5], by delivering treatment plans with steep dose gradients between target volumes and neighbouring organs at risk. Reduced volume of nearby normal tissues exposed to high doses of radiation and minimised planned treatment volume (PTV) margins on the order of 2-3 mm are two benefits of SBRT over conventional radiation treatments, which are often plagued by geometric uncertainty. In close proximity to the spinal cord, SBRT has been shown to deliver doses that are biologically efficacious [70 Gy]. The capacity to circumvent radioresistant tumour morphologies brought on by increasing rates of irreparable DNA damage and the process of endothelial cell death is another benefit of SBRT for primary spine tumours. This phenomena is exclusive to high dose, single fraction regimens. These processes allow specific SBRT regimens to overcome radioresistant morphologies and eliminate the histological reliance on local control, as shown in a clinical validation study at one institution. Chordomoma, chondrosarcoma, and osteogenic sarcoma are among the primary spinal tumours that are thought to be resistant to traditional fractionated radiation treatment [6-9]. Hence, more and more therapy paradigms are being established on SBRT in order to take advantage of its biologic benefits.

Practical Considerations Modeling

The chapter on SBRT in the spinal metastatic context thoroughly details the technical considerations for paraspinal SBRT simulation. Intrafractional motion control has been detailed before in relation to institutional methods for immobilisation, modelling, planning, and therapy delivery. According to Yamada et al. (2005), paraspinal SBRT should be administered using advanced inverse treatment planning algorithms that modulate intensity, individualised immobilisation using noninvasive body frames, and treatment delivery guided by images. Treatment administration and intrafractional motion control, like any SBRT technique, need to be customised to the specific treatment platform. To help delineate the spinal cord and any epidural component of illness, patients at Memorial Sloan Kettering Cancer Centre (MSKCC) undergo supine computed tomography (CT) simulation followed by a myelogram. On a case-by-case basis, we run PET-CT scans and inject contrast into the veins to see what happens [10-14]. To aid in target volume and spinal cord contour delineation, it is possible to integrate pretreatment MRI data with the treatment planning scan. Patients with lesions at or below T4 are often immobilised with an alpha cradle and a bespoke cradle; patients with lesions above T4 are typically immobilised with an alpha cradle and a five-point mask. To ensure the myelography is adequate, axial CT pictures are taken at 2 mm intervals and uploaded to the system for treatment planning .

Goal Establishment

To define target volumes, one should utilise the formal ICRU terminology. Using all the available clinical information and imaging modalities, such as MRI, CT, myelography, plain films, and functional imaging investigations like PET-CT, the gross tumour volume (GTV) should be defined as the total extent of the gross tumour. If a tumour is present, the GTV should incorporate all of its epidural and paraspinal components. Subclinical illness spread to neighbouring soft and bone tissues should be included when calculating the clinical target volume (CTV). The spinal column and any affected pedicle(s) typically make up the CTV for spinal column lesions. It is also possible to treat with just the GTV if the tumour has not spread to the pedicles or posterior components of the vertebrae and the rest of the vertebral body is clear. To guarantee sufficient coverage of the CTV target while preserving the surrounding normal tissues, PTV margins should be created case by case taking into account all relevant criteria. When expanding a PTV's contour, it's important to consider factors like the prescription dose-fractionation schedule, the degree of uncertainty related to various treatment platforms and immobilisation procedures, and the strategies employed for managing motion both within and between fractions. Margin sizes between CTV and PTV should normally be 3 mm or smaller; however, this can be adjusted at the treating physician's discretion to accommodate important structures including the dural margin [15-19]. While encircling the whole GTV and CTV, the PTV must never cross over into the spinal cord or cauda equina. Future developments in immobilisation and image guidance methods should make it possible to further narrow the CTV to PTV margin. Primary spinal tumours provide with particularly intricate CTV generation challenges. Worries about tumour spread beyond the GTV are especially pertinent in spinal sarcomas and chordomas. Due to the high risk of functional or neurological damage associated with wide marginal excision of microscopic illness, radical wide local excision with definitive purpose is only recommended for 10-15% of mobile spine sarcomas. Target volumes and CTV expansions tend to be bigger than those observed in metastatic tumours due to this tendency for microscopic extension beyond the gross tumour. For instance, sacral chordomas often return to the same spot in the piriformis muscle. Consequently, when delineating a CTV, it is important to take into account not just the surrounding soft and muscle tissue that could be affected by microscopic examination, but also any areas that could have been contaminated by a needle biopsy or previous surgical manipulation, such as during a definitive open resection. Patients having surgery as a part of their final treatment options for primary spinal tumours should have their risk of wound toxicity taken into account [20, 21]. In order to reduce the risk of radiation-related wound complications, it is recommended to avoid irradiating the soft tissues nearby the perioperative area if possible. In addition, when considering wound reconstruction following surgical resection, it is imperative to extensively spare any skin or muscles that could be utilised in a planned tissue flap technique.

Strategy and Execution of Treatment

The treatment platform, planning system, and other clinical variables must be considered in the treatment planning process. Here at MSKCC, we use our own software to do inverse treatment planning with intensity modulation. A fluence-based gradient search optimisation algorithm is used to develop treatment plans. Typically, 7-9 coplanar beams supplied with dynamic multi-leaf collimation are used. Maximising the percentage of PTV getting the prescribed dosage without exceeding normal tissue dose limits is achieved by normalising plans to the 100% isodose line. Using 6 and/or 15 MV photons, the 100% isodose line is prescribed treatment. For treatments using a single fraction, the maximum allowable dose to the spinal cord is 14 Gy. The inverse planning optimisation algorithm takes into account additional organ-specific institutional dose volume limitations. The CyberKnife technology, which utilises robotic image-guiding and non-isocentric circular collimated beams, is used to administer treatments at Stanford University. Inverse planning and the commercial software Multi-Plan are used to construct the treatment plans. The treatment plans that are produced usually include 100-150 beams that are guided by one to three collimators with diameters ranging from 5 to 35 mm. The prescription dose is defined according to the ideal coverage of the target volume, and plans are normalised to the maximum dose. Before treatment, patients undergo pretreatment three-dimensional (3D) kV cone beam CT (CBCT) imaging to align the simulation scan with the regional internal target bony anatomy. This is done while the patient is immobilised and in the room with the lasers. If additional CBCT imaging is required to validate location, it is used to correct rotational and translational faults. Prior to treatment, 2D kV orthogonal verification scans are taken to ensure proper patient alignment [22-25]. While a patient is receiving therapy, infrared imaging is utilised to track their every motion. When there is movement greater than 2 mm, treatment is halted and the positioning procedure is repeated.

Use in Clinical Settings Requirements for Inclusion

Nocturnal Lesion

Several studies have shown that SBRT can be helpful in treating intradural tumours like meningiomas, schwannomas, and neurofibromas. Although these lesions usually don't cause any problems, they can grow aggressively and cause a lot of pain and neurologic impairments because of the mass impact in the spinal canal. Although surgical resection is still the gold standard for treatment, SBRT offers a promising alternative for individuals for whom resection is either not an option or for whom minimal morbidity is an absolute therapeutic requirement. As an example, SBRT can arrest or reverse mass effect, producing significant improvements in quality of life and function with minimal associated morbidity, in patients with recurrent or multiple lesions, such as those with familial syndromes like neurofibromatoses, schwannomatosis, or Von Hippel-Lindau syndrome. Using SBRT for common extradural benign spine tumours such as osteoblastoma, osteoid osteoma, giant cell tumour of bone, aneurysmal bone cyst, and Langerhans cell histiocytosis has been rarely done in clinical practice. No evidence-based recommendations can be provided on the management of these benign lesions, hence it is recommended that each case be evaluated individually [26-29]. Ideally, their treatment should adhere to a set regimen.

Cancerous Growths

Multimodality therapy, which incorporates surgery, radiation therapy, and chemotherapy as needed to optimise the therapeutic ratio, should be considered for patients with primary malignant spine sarcomatous tumours, especially osteogenic sarcomas, malignant peripheral nerve sheath tumours, and chondrosarcomas. When a soft tissue sarcoma is located deep in the trunk, such as in the paraspinal region, the recurrence rate is high in that area. En bloc resection to attain a broad margin is essential for surgical cure, yet achieving negative surgical margins is infamously difficult for primary spine sarcomas. Definitive en bloc resection is only an option for 10-15% of individuals with primary spine tumours. Bilsky et al. published a series of 70 spine sarcomas treated between 1985 and 1997, and they found that when primary spinal sarcomas are surgically removed along with adjuvant post-operative conventionally fractionated radiation therapy, the results are suboptimal, with poor local control and an overall survival rate of 26 months. Therefore, wide resection is of utmost importance. Furthermore, recurrence rates with surgery alone are high and adjuvant therapy is necessary, even with the en bloc resection techniques pioneered by Tomita, Boriani, and Gokaslan. Over the course of 22 patients, Boriani documented low-grade chondrosarcomas of the movable spine; the median follow-up for these individuals was about 70 months. The researchers discovered that 25% of patients who underwent en bloc resection and 100% of patients who underwent surgical curettage experienced recurrence, even after using selective low dose conventionally fractionated radiation [30, 31]. Like spinal sarcomas, chordomas are infamously hard to control locally and, as a result, often develop insidiously. Once again, a full surgical excision is necessary for a cure; a partial excision increases the likelihood of local recurrence. Surgery alone is associated with recurrence rates of 40-50% .

Additionally, traditional fractionated radiation therapy regimens are infamously ineffective against chordomas. Despite using particle beam therapy to attain doses on the order of C80 CGE through primary radiation, local recurrence rates continue to surpass 50%. Even after administering dose-escalated radiation doses of 66 Gy with image guidance and intensity control, recurrence rates remain high with conventionally fractionated radiation therapy for different forms of primary spine tumours. In their case series, Terezakis et al. detailed 27 individuals who underwent radiation treatment after surgery to remove tumours from their spines; 23 of these patients had original tumours. The local recurrence rate was 26% and the median time to progression was 9.4 months at a median dosage of 66 Gy in 33 portions. Neoadjuvant hypofractionated SBRT after surgical resection is looking like a promising therapy paradigm in light of this body of evidence. Consequently, SBRT before surgery should be seriously explored. In randomised trials of sarcomas, the role of preoperative radiation therapy has been proven. The sarcoma literature has long advocated for hypofractionated regimens made possible by SBRT as a means to combat the radioresistant characteristics of these tumours.

Studies Looking Back

Internal Malignancies

Paraspinal SBRT has been discussed mostly in relation to extradural primary spine tumours, however there is some indication that it can be effective for intradural and intramedullary tumours as well. The biggest series of extramedullary intradural tumours treated with SBRT was described by colleagues from Stanford University. An average of 103 tumours (32 meningiomas, 47 schwannomas, and 24 neurofibromas) were treated with a 19.4 Gy dosage over 2 fractions, utilising either single or multi-fraction dosing regimens. After an average of 33 months of follow-up, all tumours were still under radiographic control, with the exception of 1 (40% of tumours shrank in size; 59% stayed stable). Outcomes regarding pain response were best for patients with meningiomas and schwannomas, with a rate of improvement or stability of 89% for schwannomas and 100% for meningiomas. Neurofibromas, on the other hand, produced worse results (67%). In a separate series of 73 cases, Gerszten et al. (2008) detailed the radiosurgery treatment of extramedullary benign tumours located within the spinal cord. Neurofibromas, schwannomas, and meningiomas made up the majority of the tumours that were treated. SBRT was administered for a range of reasons, such as when illness progressed following surgical resection, as a planned adjuvant treatment following surgery [34-37], or as a final option for treating unresectable tumours. Median follow-up was 37 months, and maximal intratumoral doses ranged from 15 to 25 Gy. All patients who were treated were able to achieve long-term radiographic control, and a staggering 73% of those patients reported a considerable improvement in their symptoms. One patient at Stanford University and three patients at the University of Pittsburgh Medical Centre suffered radiation myelopathy as a consequence of treatment. Despite their exploratory nature, these trials do point to the potential use of single or multi-fraction SBRT for benign spinal tumours, particularly in situations when open surgery is not an option. Ryu et al. investigated SBRT's function in the treatment of intramedullary tumours of the spinal cord [37-41]. Using SRS, they documented the treatment of ten intramedullary tumours (7 hemangioblastomas and 3 ependymomas) from 1998 to 2003. Tumours that returned, tumours that were too large to remove surgically, medical reasons against surgery, or patient refusal to have surgery were among the many reasons radiation was administered. The average radiation dose was 21 Gy, with a range of 18–25 Gy administered in 3–5 halves. There were no major side effects associated with the treatment, with a median follow-up of 12 months. Three tumours demonstrated a partial response, while six tumours remained radiographically stable without progression. A more extensive dataset from Stanford University corroborated these findings; it documented 32 individuals (26 with von Hippel-Lindau disease) who underwent stereotactic radiosurgery for the treatment of 92 hemangioblastomas of the spinal cord or brain between 1992 and 2007. On average, the tumour volume was 1.8 cm3, and the radiation dose to its periphery was 23.4 Gy. Radiosurgery alleviated symptoms associated with lesions in 36 out of 41 tumours that were symptomatic, and the local control rates at 3 and 5 years were 82% and85%, respectively, over a median follow-up of 69 months. Both studies found that SBRT was a safe, effective, and practical method of targeting intramedullary spinal lesions with high dose conformal radiation while exposing the rest of the spine to less radiation. According to these results, SBRT is a viable option for patients with intramedullary tumours who do not want open surgery.

Cancerous Growths Outside the Brain

For malignant extradural spinal tumours, small retrospective investigations have shown that hypo-fractionated or single fraction SBRT is effective. A case report of an L3 chordoma that was given 24 Gy in one portion with decisive purpose was published by Wu et al. (2009). Because of their other health conditions, this patient was not a good candidate for surgery. The patient underwent kyphoplasty 8 weeks after finishing single fraction SBRT, and a biopsy revealed live disease. Due to concerns about the patient's interval tumour progressing sixteen weeks after single fraction SBRT, surgical excision was performed. This open resection specimen showed chordoma necrosis of 99% according to the pathology report. The remarkable pathologic response to single fraction radiation has resulted in the increased use of this neoadjuvant treatment paradigm for primary spinal tumours. This is because tumours showing this level of response may not require en bloc resection if there is substantial necrosis and sterilised margins. Early follow-up data from a number of small series investigating the efficacy of high-dose stereotactic radiosurgery in treating skull base chordomas seems encouraging. Two more studies that utilised hypofractionated carbon ion therapy for large sacral chordomas found that with a 16 fraction regimen of about 4.4 GyE/fraction, local control rates ranged from 94% to 100% with a median follow-up of 43 to 58 months. There was a marked decrease in tumour volumes after therapy in both trials. These encouraging preliminary findings point to SBRT as a potentially game-changing new paradigm for chordoma treatment. Among other histologies, Levine et al. (2009) detailed SBRT's success in treating both primary and metastatic spinal sarcomas [42-45]. Out of the thirty lesions that were treated, fourteen were

primary spine sarcomas: four fibromyxosarcomas, three chondrosarcomas, two leiomyosarcomas, two undifferentiated sarcomas, one dedifferentiated liposarcoma, one angiosarcoma, and one synovial sarcoma. Surgical excision and SBRT were used to treat seven primary tumours, while definitive SBRT was administered to seven more. Cyberknife was used for the treatment. Doses administered to the 70-85% isodose lines varied from 20 to 36 Gy delivered in 1-5 portions, which was the actual treatment range. We provided 150-300 pencil beams with the plans. Seven patients who underwent SBRT for primary spine sarcomas reported significant improvement in pain and survival rates at 33 months on average. Recurrences occurred in two patients, while three others had partial tumour regression. One patient experienced nausea as an acute toxicity, and another patient felt generally unwell. Among the late toxicities, one patient required a diverting colostomy due to a fistula that developed between the tumour cavity and the rectum in a sacral sarcoma patient. Three patients in the surgery plus SBRT group received treatment before surgery, while four patients received treatment after the fact. The dosing regimen was the same as the previous group. En bloc resection revealed total tumour necrosis in one patient who had received prior treatment. Two further patients perished as a result of both local and distant disease, despite having viable disease during surgery. With an average follow-up of 43.5 months, all four patients who underwent postoperative treatment survived the procedure and showed no signs of disease, despite having positive margins during surgery. Radiculopathy caused by treatment in two patients was transient and went away on its own. The outcomes of hypofractionated stereotactic radiation treatment for the cervical spine and skull base were documented by Gwak et al .



Figure 1. A groundbreaking imaging technique allows doctors to track a substance called 2HG that a subset of gliomas overproduces.

Of the nine patients in their cohort, four underwent surgical treatment for chondrosarcoma and chordoma of varying severity. Conformity indices varied between 1.01 and 1.83, and the prescribed dosages were between 21 and 43.6 Gy delivered in 3 to 5 portions. The dosimetric study showed that the postoperative surgical group had a reduced relative dose to volume percent of any essential structures compared to the non-surgical group, indicating that surgical decompression may have a dosimetric benefit. Recurrence occurred in just one patient at a median follow-up of twenty-four months. Minor acute toxicities included short-lived esophagitis and otitis media. Two patients experienced radiation-induced myelopathy as a late toxicity. Radioresistant tumours, such as chordomas and chondrosarcomas, can be safely and effectively treated with SBRT, according to the authors. British researchers Martin et al. (2011) detailed the outcomes of a group of patients whose spine tumours had undergone SRS treatment. Primary malignancies accounted for 14 of the 53 lesions that were treated. The prescribed doses can be anything from 8 to 30 Gy divided into 1-3 portions. Overall survival was 65% and local control was 91% for the full cohort of 53 patients with a median follow-up of 11.1 months. Grade 3 or higher toxicity occurred in just three lesions; these were all short-lived pain flare episodes that improved once corticosteroids were administered.

Management of Chronic Illness

When it comes to treating recurring primary spine tumours, the same rules apply as when dealing with metastatic disease: local control is key, and additional treatment modalities like radiation therapy and surgery should be used as safely as possible. Higher radiation doses are still better than lower ones, even in the repeated irradiation scenario, so it's reasonable to think about gradually increasing the dosage. Using a 6 Gy 9 5 regimen instead of a 4 Gy 9 5 regimen significantly reduced local failures following SBRT for recurring paraspinal tumours, according to research by Damast et al. (2011), without increasing the incidence of myelopathy. Novel techniques such epidural plaque brachytherapy, HDR interstitial brachytherapy, vascular embolisation, and intra-arterial chemotherapy are used in the recurring scenario of primary spine tumours because radiation therapy and surgery can be difficult to repeat in certain cases with multiple recurrent tumours.

Health Risks

Metastatic spine tumours treated with SBRT have similar toxicity to single fraction or hypofractionated radiation as primary spine tumours. With a late myelopathy rate of less than 1%, a vertebral body fracture incidence of up to 40%, and a grade C 3 late oesophageal toxicity rate of 5%, these are thoroughly detailed in the chapter on SBRT for metastatic spine tumours. For paraspinal SBRT, especially with single fraction regimens, patients are typically pre-medicated with dexamethasone to avoid immediate treatment-related swelling and discomfort. For 7-10 days prior to and after SBRT, practitioners should think about limiting patients' access to cytotoxic or other systemic treatments due to concerns of synergistic or potentiating interactions.

Accurate Stereotactic Radiation for Brain Cancers

One ground-breaking method for treating tumours is stereotactic ablative radiation treatment (SABR/SBRT). When used to treat spinal tumours, its benefits become even more apparent. Its many uses include radiation therapy on its own, as well as in the prevention and treatment of spinal tumours before and after surgery. Stereotactic radiation for spinal tumours has a unique and distinct process compared to conventional radiation. Additionally, SBRT has anti-vascular effects, in situ vaccination effects, and an abscopal effect, in addition to producing more DNA double-strand breaks and resulting in less DNA damage repair than conventional radiation. This study aims to summarise the existing literature on selective ablation of spinal tumours (SABR) as a therapy option. We will also examine the features of SABR and spinal tumours, as well as the clinical effectiveness and safety of SABR in this context. Furthermore, we raised a number of concerns regarding the normal dosage for treatment, post-treatment follow-up, and SABR for spinal tumours. We also offered future research directions by making predictions about the management of spinal tumours, the advancement of SABR, the integration of SABR with other treatments in multi-modality settings, and other trends in future development. Both primary and metastatic malignancies frequently manifest in the spine. Spinal metastasis is a common topic of discussion and evaluation in cancer treatment, particularly with the recent advances in tumour targeting medicines and immunotherapy. The close proximity of spinal tumours to the major nerve systems makes treatment more challenging. Because it is difficult to raise the dosage of conventional radiation near the spinal cord, this treatment is more of a palliative measure than a curative one.

How SABR Works and What Makes It Special

The SABR process Compared to conventional radiation, the SABR process used to treat spinal tumours is very different. There are additional side effects associated with SABR, including anti-vascular effects, in situ vaccination effects, and an abscopal impact, in comparison to conventional radiation. Additionally, SABR causes less repairs to DNA damage and more double-strand breaks. Consequently, stereotactic radiation is a highly successful method for treating local ablation. On top of that, it helps with disease management on a local level and has a number of far-reaching effects that make overall control better .

Identifying SABR Features

When it comes to treating spinal tumours, the benefits of SABR are invaluable. To start, different types of spinal tumours (primary and metastatic) have different pathologies; for example, certain tumour cells are more radioresistant than others. SABR is superior to conventional radiotherapy for radioresistant tumours because it achieves high-dose fractions with a shorter course of radiation. Secondly, the majority of patients with spinal tumours experience pain, and a brief course of SABR irradiation can expedite the relief of discomfort. As a third point, SABR approaches can

guarantee treatment accuracy by monitoring motion in the between radiation doses. But conventional radiation therapy makes it difficult, if not impossible, to walk around while being treated. Fourth, a quick dose reduction outside the target is necessary because spinal tumours are frequently located near the spinal cord. Using SABR, the dosage can be quickly reduced from the treatment area to the surrounding area. Stereotactic radiation also typically has shorter treatment days compared to other radiotherapy modalities (such IMRT), which means less money spent on staffing and upkeep of hospital facilities. Because of its distinct benefits, SABR is quickly becoming a preferred method of treating spinal tumours. Keep in mind that SABR isn't necessarily the way to go for every patient. Take patients whose prognosis is good as an example.

The Use of SABR in the Treatment of Brain Tumours

Multimodality treatments for spinal tumours involving new systemic treatments are becoming more and more incompatible with conventional radiotherapy due to its disadvantages. When used in combination with other treatment modalities, SABR has demonstrated low toxicity and excellent efficacy for spinal tumours. There are three main ways SABR is used to treat spinal tumours: as a primary treatment, as a repeat treatment after other forms of radiation, and as a postoperative treatment.

SABR as Primary Treatment

SABR as primary treatment is the most important way that SABR is used for spinal tumors, and also the most important research area for SABR in spinal tumors. A representative study of SABR showed that the local control rate of SABR was >80% , and local control was even higher (>90%) in other studies , greatly improved compared with traditional radiotherapy where recurrence rates are close to 80% . Moreover, SABR also shows significant benefit in pain relief. The efficacy of SABR promotes the change in radiotherapy for spinal tumor from palliative treatment with traditional radiotherapy to definitive radiation with SABR , improving local control and quality of life for patients with spinal tumors .

SABR Treatment After Prior Radiotherapy

Recurrence after prior radiotherapy is common in the treatment of spinal tumor. Due to the dose limitation on spinal cord, ordinary radiotherapy cannot be repeated at sites that received prior radiotherapy. Therefore, SABR is the only option for repeat radiation. The results . demonstrated that repeat SABR achieved good efficacy in controlling tumor-related pain .

The SABR after surgery

When it comes to individuals suffering from symptomatic single-level MESCC, Patchell et al. established the importance of decompressive surgery. As a gold standard for MESCC treatment, this article proved the efficacy of surgery followed by radiation. Additionally, stereotactic radiation provides higher benefits for postoperative treatment of spinal tumours, according to multiple studies. Despite substantial variation in treatment dose and fraction among published series, stereotactic radiation has the potential to alleviate pain and improve local control (with an estimated rate of 80–90%). In conclusion, SABR is an effective primary treatment, salvage treatment after previous radiotherapy, and postoperative radiotherapy for spinal tumours.



Figure 2. Describe SBRT and its effects on spinal tumours. It's hard to find anything else like SBRT. Because SBRT is an ablative treatment, it is "absolutely different" from conventional fractionated radiation.

Recognising the Interplay Between Radiation-Related Adverse Events and Tumour Control During Treatment: Treatment Dosage Determination

The objective of treating tumours is to bring the tumour under control while minimising harm to the surrounding tissue. Unfortunately, tumour control often involves harming healthy tissue in the process. Spinal cord damage is a common consequence of untreated spinal tumours. Thus, radiation treatment for spinal tumours is still more beneficial than harmful. To protect neurologic structures in the spinal cord, the current standard radiation doses used to treat spinal tumours are often quite modest. There are essentially two scenarios in clinical practice when deciding on a dosage for spinal cord irradiation. To begin, it is essential to accomplish both aims simultaneously in order to establish spinal tumour control without injuring the spinal cord. Secondly, reaching an ideal dosage for tumour management is of the utmost importance and top priority in cases where unchecked tumour growth results in spinal cord injury. Based on these findings, additional research is needed to determine the optimal SABR dosage for treating spinal tumours.

Examples of Real-World Situations

Example 1: L3 Chordoma Response to Fractional SBRT Is Nearly Complete from a Pathological Perspective The pathological reaction of a chordoma specimen following single fraction SBRT therapy indicates the biological efficiency of SBRT in primary spine tumours in the first example. A guy in his seventies who had been suffering from lower back discomfort sought medical attention. There was no sign of metastasis in the imaging study that showed an L3 spinal tumour. Chordomoma was discovered after an open surgical biopsy. Due to many medical co-morbidities, the patient was not considered a surgical candidate and chose to have definitive SBRT instead. After being immobilised in a bespoke body cradle, the patient underwent CT simulation with myelography. There was a lesion in the L3 vertebral body where the isocenter was implanted. Both the gross tumour volume (GTV) and the critical tumour volume (CTV) were used to represent potential locations for microscopic tumour spread. The PTV was created by expanding the CTV by 3 mm and making adjustments so that the spinal cord and cauda equina did not intersect. This PTV had a capacity of 90 cm3. It was possible to locate nearby healthy tissues, such as the cauda equina, spinal cord, small intestine, and kidneys. A dose of 24 Gy was prescribed and delivered to the planning target volume in a single fraction using an intensity-modulated plan. The spinal cord and cauda equina were both limited to a maximum point dose of 14 Gy and 16 Gy, respectively, during the planning phase. Intrafraction motion tracking using an infrared camera and CBCT localisation were utilised to administer the treatment. Symptoms of acute toxicity were experienced by some patients. The patient was referred to the operating room sixteen weeks following the completion of SBRT because of probable interval tumour progression and new-onset mechanical radiculopathy in the tumour bed. There were no complications during the L3 corpectomy and anterior reconstruction that was done using an anterior retroperitoneal technique. This open resection specimen showed chordoma necrosis of 99% according to the pathology report. Radionecrosis of the neighbouring bone did not occur. The patient's recovery went smoothly. This case study shows that tumour histologies that are considered resistant to traditional fractionated radiation therapy can be effectively treated with high dose, single fraction SBRT.

Cordoba Sacralis

When it comes to large primary sacral tumours, SBRT is the way to go because en bloc resection techniques, such sacrectomy, can cause serious postoperative complications like neurologic, functional, and mechanical issues. Take a 65-year-old guy who complained of lower-quality bowel motions and discomfort when sitting as an example. An MRI scan was one of the imaging studies that revealed a 7 cm tumour with heterogeneous appearance that was located in the sacrum. The results of the biopsy confirmed the diagnosis of conventional chordoma, which is characterised by the entrapment of epithelioid and vacuolated cells in a myxoid matrix. In lieu of surgical intervention, the patient has chosen to undergo definitive radiation therapy for his condition. A single fraction SBRT technique was chosen over a high dosage conventionally fractionated approach because of the tumor's aggressiveness and size. While lying face down in a specially designed cradle, the patient was subjected to CT simulation. Contours were drawn around target and important normal structures. We devised a treatment regimen that would expose the PTV to 24 Gy. It seems like no problems were encountered throughout the delivery of this one portion. The patient's pain levels dropped significantly three months after treatment. Results from the chordoma's treatment were clearly visible on imaging, with the tumor's size much reduced in both the axial and sagittal planes and a noticeable area of necrosis in the tumor's

centre. There were no treatment-related side effects, and there was no sign of illness progression at the most recent follow-up appointment.

A Spinal Tumour That Isn't Malignant Yet

Following subtotal removal of a left C3-4 schwannoma, this 39-year-old lady continued to have periodic tingling, burning pain that extended down her left arm, and symptoms of the tumour. She received 16 Gy in 1 fraction of SBRT using the Cyberknife technique. at 2 years, the MRI scan remained steady

CONCLUSION

Due to its ability to safely increase dosages and overcome the radioresistant phenotype shown in certain primary spine tumours, SBRT—and specifically single fraction radiosurgery—is an encouraging new approach to treating these tumours. Curative treatment with minimal neurologic, mechanical, and functional damage is possible with SBRT alone or in conjunction with open surgery. Extended follow-up and the establishment of prospective clinical studies will ascertain the spinal radiosurgery's long-term effectiveness.

REFERENCES

1. Kepka L, DeLaney TF, Suit HD, Goldberg SI (2005) Results of radiation therapy for unresected soft-tissue sarcomas. Int J Radiat Oncol Biol Phys 63(3):852–859.
2. Kawashiro S, Harada H, Katagiri H, Asakura H, Ogawa H, Onoe T, et al. Reirradiation of spinal metastases with intensity-modulated radiation therapy: an analysis of 23 patients. J Radiat Res. (2016) 57:150– 6.
3. Mahadevan A, Floyd S, Wong E, Jeyapalan S, Groff M, Kasper E. Stereotactic body radiotherapy reirradiation for recurrent epidural spinal metastases. Int J Radiat Oncol Biol Phys. (2011) 81:1500–1505.
4. Thibault I, Campbell M, Tseng CL, Atenafu EG, Letourneau D, Yu E, et al. Salvage stereotactic body radiotherapy (SBRT) following in-field failure of initial sbrt for spinal metastases. Int J Radiat Oncol Biol Phys. (2015) 93:353– 60.
5. Patchell RA, Tibbs PA, Regine WF, Payne R, Saris S, Kryscio RJ, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet. (2005) 366:643– 8.
6. Gerszten PC, Germanwala A, Burton SA, Welch WC, Ozhasoglu C, Vogel WJ. Combination kyphoplasty and spinal radiosurgery: a new treatment paradigm for pathological fractures. J Neurosurg Spine. (2005) 3:296–301.
7. Rock JP, Ryu S, Shukairy MS, Yin FF, Sharif A, Schreiber F, et al. Postoperative radiosurgery for malignant spinal tumors. Neurosurgery. (2006) 58:891– 8.
8. Gerszten PC, Monaco ER. Complete percutaneous treatment of vertebral body tumors causing spinal canal compromise using a transpedicular cavitation, cement augmentation, and radiosurgical technique. Neurosurg Focus. (2009) 27:E9.
9. Moulding HD, Elder JB, Lis E, Lovelock DM, Zhang Z, Yamada Y, et al. Local disease control after decompressive surgery and adjuvant high-dose single-fraction radiosurgery for spine metastases. J Neurosurg Spine. (2010) 13:87–93.
10. Massicotte E, Foote M, Reddy R, Sahgal A. Minimal access spine surgery (MASS) for decompression and stabilization performed as an out-patient procedure for metastatic spinal tumours followed by spine stereotactic body radiotherapy (SBRT): first report of technique and preliminary outcomes. Technol Cancer Res Treat. (2012) 11:15–25.
11. Al-Omair A, Masucci L, Masson-Cote L, Campbell M, Atenafu EG, Parent A, et al. Surgical resection of epidural disease improves local control following postoperative spine stereotactic body radiotherapy. Neuro Oncol. (2013) 15:1413–9.

12. Laufer I, Sciubba DM, Madera M, Bydon A, Witham TJ, Gokaslan ZL, et al. Surgical management of metastatic spinal tumors. Cancer Control. (2012) 19:122–8.

13. Wardak Z, Bland R, Ahn C, Xie XJ, Chason D, Morrill K, et al. A phase II clinical trial of SAbR followed by immediate vertebroplasty for spine metastases. Int J Radiat Oncol Biol Phys. (2019) 104:83– 89.

14. Redmond KJ, Sciubba D, Khan M, Gui C, Lo SL, Gokaslan ZL, et al. A phase 2 study of post-operative stereotactic body radiation therapy (SBRT) for solid tumor spine metastases. Int J Radiat Oncol Biol Phys. (2020) 106:261– 8.

15. Laufer I, Iorgulescu JB, Chapman T, Lis E, Shi W, Zhang Z, et al. Local disease control for spinal metastases following "separation surgery" and adjuvant hypofractionated or high-dose single-fraction stereotactic radiosurgery: outcome analysis in 186 patients. J Neurosurg Spine. (2013) 18:207–14.

16. Giaj-Levra N, Niyazi M, Figlia V, Napoli G, Mazzola R, Nicosia L, et al. Feasibility and preliminary clinical results of linac-based Stereotactic Body Radiotherapy for spinal metastases using a dedicated contouring and planning system. Radiat Oncol. (2019) 14:184.

17. Versteeg AL, Hes J, van der Velden JM, Eppinga W, Kasperts N, Verkooijen HM, et al. Sparing the surgical area with stereotactic body radiotherapy for combined treatment of spinal metastases: a treatment planning study. Acta Oncol. (2019) 58:251–6.

18. Choi CH, Kim JH, Kim JI, Park JM. Comparison of treatment plan quality among MRI-based IMRT with a linac, MRI-based IMRT with tri-Co-60 sources, and VMAT for spine SABR. PLoS ONE. (2019) 14:e0220039.

19. Glicksman RM, Tjong MC, Neves-Junior WFP, Spratt DE, Chua KLM, Mansouri A, et al. Stereotactic ablative radiotherapy for the management of spinal metastases: a review. JAMA Oncol. (2020) 6, 567–77.

20. Mossa-Basha M, Gerszten PC, Myrehaug S, Mayr NA, Yuh WT, Jabehdar Maralani P, et al. Spinal metastasis: diagnosis, management and follow-up. Br J Radiol. (2019) 92:20190211.

21. Thibault I, Chang EL, Sheehan J, Ahluwalia MS, Guckenberger M, et al. Response assessment after stereotactic body radiotherapy for spinal metastasis: a report from the SPIne response assessment in Neuro-Oncology (SPINO) group. Lancet Oncol. (2015) 16:e595–603

22. Krishnan S, Foote RL, Brown PD, Pollock BE, Link MJ, Garces YI (2005) Radiosurgery for cranial base chordomas and chondrosarcomas. Neurosurgery 56(4):777–784

23. Levine AM, Coleman C, Horasek S (2009) Stereotactic radiosurgery for the treatment of primary sarcomas and sarcoma metastases of the spine. Neurosurgery 64(2):A54–A59.

24. Lovelock DM, Hua CH, Wang P, Hunt M, Fournier-Bidoz N, Yenice K, Toner S, Lutz W, Amols H, Bilsky M, Fuks Z, Yamada Y (2005a) Accurate setup of paraspinal patients using a noninvasive patient immobilization cradle and portal imaging. Med Phys 32(8):2606–2614.

25. Lovelock DM, Hua C, Wang P, Hunt M, Fournier-Bidoz N, Yenice K, Toner S, Lutz W, Amols H, Bilsky M, Fuks Z, Yamada Y (2005b) Accurate setup of paraspinal patients using a noninvasive patient immobilization cradle and portal imaging. Med Phys 32(8):2606–2614

26. Lunsford LD, Niranjan A, Martin JJ, Sirin S, Kassam A, Kondziolka D, Flickinger JC (2007) Radiosurgery for miscellaneous skull base tumors. Prog Neurol Surg 20:192–205.

27. Martin AG, Cowley IR, Taylor BA, Cassoni AM, Landau DB, Plowman PN (2011) (Stereotactic) radiosurgery XIX: spinal radiosurgery—two year experience in a UK centre. Br J Neurosurg.

28. Martin JJ, Niranjan A, Kondziolka D, Flickinger JC, Lozanne KA, Lunsford LD (2007) Radiosurgery for chordomas and chondrosarcomas of the skull base. J Neurosurg 107(4): 758–764.

29. Moss JM, Choi CY, Adler JR, Jr., Soltys SG, Gibbs IC, Chang SD (2009) Stereotactic radiosurgical treatment of cranial and spinal hemangioblastomas. Neurosurgery 65(1):79–85 discussion 85.

30. Osaka S, Kodoh O, Sugita H, Osaka E, Yoshida Y, Ryu J (2006) Clinical significance of a wide excision policy for sacrococcygeal chordoma. J Cancer Res Clin Oncol 132(4): 213–218.

31. Rao G, Suki D, Chakrabarti I, Feiz-Erfan I, Mody MG, McCutcheon IE, Gokaslan Z, Patel S, Rhines LD (2008) Surgical management of primary and metastatic sarcoma of the mobile spine. J Neurosurg Spine 9(2):120–128.

32. Rose PS, Laufer I, Boland PJ, Hanover A, Bilsky MH, Yamada J, Lis E (2009) Risk of fracture after single fraction imageguided intensity-modulated radiation therapy to spinal metastases. J Clin Oncol 27(30):5075–5079.

33. Ryu SI, Chang SD, Kim DH, Murphy MJ, Le QT, Martin DP, Adler JR Jr (2001) Image-guided hypo-fractionated stereotactic radiosurgery to spinal lesions. Neurosurgery 49(4): 838–846

34. Ryu SI, Kim DH, Chang SD (2003) Stereotactic radiosurgery for hemangiomas and ependymomas of the spinal cord. Neurosurg Focus 15(5):E10.

35. Sachdev S, Dodd RL, Chang SD, Soltys SG, Adler JR, Luxton G, Choi CY, Tupper L, Gibbs IC (2011) Stereotactic radiosurgery yields long-term control for benign intradural, extramedullary spinal tumors. Neurosurgery 69(3): 533–539 discussion 539.

36. Schwab JH, Healey JH, Rose P, Casas-Ganem J, Boland PJ (2009) The surgical management of sacral chordomas. Spine Phila Pa 1976 34(24):2700–2704.

37. Serizawa I, Imai R, Kamada T, Tsuji H, Kishimoto R, Kandatsu S, Tsujii H, Tatezaki S (2009) Changes in tumor volume of sacral chordoma after carbon ion radiotherapy. J Comput Assist Tomogr 33(5):795–798.

38. Terezakis SA, Lovelock DM, Bilsky MH, Hunt MA, Zatcky J, Yamada Y (2007) Image-guided intensity-modulated photon radiotherapy using multifractionated regimen to paraspinal chordomas and rare sarcomas. Int J Radiat Oncol Biol Phys 69(5):1502–1508.

39. Thames HD, Suit HD (1986) Tumor radioresponsiveness versus fractionation sensitivity. Int J Radiat Oncol Biol Phys 12(4):687–691.

40. Wang VY, Potts M, Chou D (2008) Sarcoma and the spinal column. Neurosurg Clin N Am 19(1):71–80.

41. Wu AJ, Bilsky MH, Edgar MA, Yamada Y (2009) Near-complete pathological response of chordoma to high-dose single-fraction radiotherapy: case report. Neurosurgery 64(2): E389 390 discussion E390.

42. doi:10.1227/01.NEU.0000338073.49649. 1A00006123-200902000-00023[pii] Yamada Y, Lovelock DM, Yenice KM, Bilsky MH, Hunt MA, Zatcky J, Leibel SA (2005) Multifractionated image-guided and stereotactic intensity-modulated radiotherapy of paraspinal tumors: a preliminary report. Int J Radiat Oncol Biol Phys 62(1):53–61.

43. Yamada Y, Bilsky MH, Lovelock DM, Venkatraman ES, Toner S, Johnson J, Zatcky J, Zelefsky MJ, Fuks Z (2008) High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions. Int J Radiat Oncol Biol Phys 71(2):484–490.

44. Yang JC, Chang AE, Baker AR, Sindelar WF, Danforth DN, Topalian SL, DeLaney T, Glatstein E, Steinberg SM, Merino MJ, Rosenberg SA (1998) Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 16(1):197–203

45. Zagars GK, Ballo MT (2003) Significance of dose in postoperative radiotherapy for soft tissue sarcoma. Int J Radiat Oncol Biol Phys 56(2):473–481.